Optical and Near-Infrared Photometry of Nova V2362 Cyg : Rebrightening Event and Dust Formation

We present optical and near-infrared (NIR) photometry of a classical nova, V2362 Cyg (= Nova Cygni 2006). V2362 Cyg experienced a peculiar rebrightening with a long duration from 100 to 240 d after the maximum of the nova. Our multicolor observation indicates an emergence of a pseudophotosphere with an effective temperature of 9000 K at the rebrightening maximum. After the rebrightening maximum, the object showed a slow fading homogeneously in all of the used bands for one week. This implies that the fading just after the rebrightening maximum ( less or equal 1 week ) was caused by a slowly shrinking pseudophotosphere. Then, the NIR flux drastically increased, while the optical flux steeply declined. The optical and NIR flux was consistent with blackbody radiation with a temperature of 1500 K during this NIR rising phase. These facts are likely to be explained by dust formation in the nova ejecta. Assuming an optically thin case, we estimate the dust mass of 10^(-8) -- 10^(-10) M_solar, which is less than those in typical dust-forming novae. These results support the senario that a second, long-lasting outflow, which caused the rebrightening, interacted with a fraction of the initial outflow and formed dust grains.Comment: 6 pages, 4 figures, 2010, PASJ, 62, 1103--1108, in pres

The 2006 November outburst of EG Aquarii: the SU UMa nature revealed

We report time-resolved CCD photometry of the cataclysmic variable EG Aquarii during the 2006 November outburst During the outburst, superhumps were unambiguously detected with a mean period of 0.078828(6) days, firstly classifying the object as an SU UMa-type dwarf nova. It also turned out that the outburst contained a precursor. At the end of the precursor, immature profiles of humps were observed. By a phase analysis of these humps, we interpreted the features as superhumps. This is the second example that the superhumps were shown during a precursor. Near the maximum stage of the outburst, we discovered an abrupt shift of the superhump period by ${\sim}$ 0.002 days. After the supermaximum, the superhump period decreased at the rate of $\dot{P}/P$=$-8.2{\times}10^{-5}$, which is typical for SU UMa-type dwarf novae. Although the outburst light curve was characteristic of SU UMa-type dwarf novae, long-term monitoring of the variable shows no outbursts over the past decade. We note on the basic properties of long period and inactive SU UMa-type dwarf novae.Comment: 9 pages, 7 figures, accepted for PAS

Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment

Abstract A 47‐year‐old male with paroxysmal nocturnal haemoglobinuria (PNH) controlled with routine ravulizumab administration suffered a massive haemolytic crisis due to choledocholithiasis. Laparoscopic cholecystectomy was performed 6 weeks after a regular ravulizumab infusion. After surgery, the patient presented with anaemia without marked elevation in lactate dehydrogenase and required two blood transfusions. Tumour necrosis factor‐α increased more than twofold with reticulocyte suppression after surgery, suggesting the involvement of myelosuppressive cytokines. This case suggests that laparoscopic surgery may be safely performed in patients with PNH receiving ravulizumab maintenance treatment. However, attention should be paid to postoperative anaemia, regardless of breakthrough haemolysis

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM)). To determine a possible biomarker for STOP-IM CML, we examined plasma miRNA expression in CML patients who were able to discontinue IM. We first screened candidate miRNAs in unselected STOP-IM patients, who had sustained UMRD after discontinuing IM for more than six months, in comparison with healthy volunteers, by using a TaqMan low-density array for plasma or exosomes. Exosomal miR-215 and plasma miR-215 were downregulated in the STOP-IM group compared to the control, indicating that the biological relevance of the plasma miR-215 level is equivalent to that of the exosomal level. Next, we performed real-time quantitative RT-PCR in 20 STOP-IM patients, 32 patients with UMRD on continued IM therapy (IM group) and 28 healthy volunteers. The plasma miRNA-215 level was significantly downregulated in the STOP-IM group (p < 0.0001); we determined the cut-off level and divided the IM group patients into two groups according to whether the plasma miR-215 was downregulated or not. The IM group patients with a low plasma miR-215 level had a significantly higher total IM intake, compared to the patients with elevated miR-215 levels (p = 0.0229). Functional annotation of miR-215 target genes estimated by the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatic tools involved cell cycle, mitosis, DNA repair and cell cycle checkpoint. Our study suggests a possible role of miR-215 in successful IM discontinuation

Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study

We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in the study. From April 2021 to September 2021, all cases (median age = 58 years) were vaccinated twice. Immunoglobulin G for SARS-CoV-2 spike protein (S-IgG) was measured at three timepoints (before the first VC, 1–5 weeks after the second VC (T1), and approximately 6 months after the second VC (T2)). S-IgG was not observed before the first VC in any participant. At T1, all cases had acquired S-IgG. There were no significant differences in S-IgG levels among groups. A paired sample comparison of median S-IgG titers between T1 and T2 in all groups showed a significant reduction in T2 S-IgG titers. There were no significant differences in S-IgG levels among groups. When all patients were analyzed, those aged ≥58 years had significantly lower S-IgG levels than those aged <58 years at T1. The BNT162b2 vaccine was highly effective in CML patients with or without TKIs, and S-IgG levels were as persistent as those in healthy individuals